Speaker Name: Prof. Keith C. Ferdinand, Professort of Medicine, Gerald S. Berenson Chair in Preventive Cardiology, Director of Preventive Cardiology, Tulane University School of Medicine, Orleans, Lousiana, USA

Watch this session to:

• Understand the AHA CKM framework and Life’s Essential 8 linking obesity, T2DM, CKD, and ASCVD to support early risk modification.
• Recognize BP as a primary driver of CKM outcomes with targets <130/80 mm Hg supported by SPRINT, STEP, and related trials.
• Identify expanded CKM risk assessment strategies using PREVENT model inputs, including uACR, HbA1c, and eGFR.
• Learn how to initiate and individualize antihypertensive therapy in T2DM and CKD with emphasis on RAS blockade in albuminuria.
• Evaluate management of obesity-related and resistant hypertension, including lifestyle therapy, GLP-1 RA, MRA, and emerging treatments.